Galderma has received a Complete Response Letter (CRL) from the FDA for Relfydess (relbotulinumtoxinA), its novel botulinum toxin formulation intended as a Botox alternative. The CRL indicates the agency requires additional data or clarification before approval can be granted, effectively blocking the product's U.S. market entry in the near term.
Regulatory
Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle
FDA rejects Galderma's new neuromodulator formulation; shares slide on failed market-entry bid.
FDA Complete Response Letter blocks Relfydess market entry; Galderma's neuromodulator expansion stalls.
Relfydess was positioned as a differentiated neuromodulator with a potentially faster onset and longer duration than existing toxins, but the regulatory pathway proved more complex than anticipated. The setback underscores the high bar for new-entity botulinum toxin approvals and the entrenched competitive advantage of AbbVie's Botox and Galderma's own Dysport. For practices, this means no near-term disruption to toxin pricing or supply dynamics; the neuromodulator market remains dominated by two players with limited new competition on the horizon.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.